How do you differentiate vector-related cardiotoxicity from payload-induced effects in histology?
A: We employ a multi-faceted approach. This includes evaluating control groups with empty vectors alongside payload-carrying vectors, and correlating histological findings with vector biodistribution data and payload expression levels (via IHC/ISH). This allows our board-certified pathologists to discern capsid-mediated inflammation from transgene-specific cellular changes.
What is your standard panel for evaluating cardiac tissue in AAV-based therapy studies?
A: Our core panel includes H&E staining for general morphology, Masson’s Trichrome for fibrosis, and specific immunohistochemistry (IHC) markers for inflammation (e.g., CD45, Mac-2) and cardiomyocyte injury (e.g., cTnI). Panels are customized based on the vector, payload, and specific study objectives in consultation with our strategic partners.
How do you address species-specific differences in cardiac response during preclinical evaluation?
A: We maintain a robust historical control database across multiple preclinical species. This allows us to contextualize findings and identify responses that deviate from known species-specific background pathology. As highlighted in recent research (PMID: 39001819), understanding species-specific glycan presentation is key to interpreting biodistribution and potential cardiac effects, a factor we integrate into our final analysis.
What is the typical turnaround time for a comprehensive cardiac pathology report?
A: Timelines are program-specific. Following tissue receipt, we provide preliminary findings to support immediate program decisions, followed by a full, peer-reviewed GxP-compliant report. Expedited timelines are available for programs approaching key decision points.
Evaluating cardiovascular safety is a primary objective in preclinical programs for novel biologics. Histological assessment must move beyond standard toxicology screens to address the specific mechanisms of action associated with gene and cell therapies. Our approach integrates advanced histology with vector biodistribution data to provide a definitive assessment of potential cardiotoxicity, de-risking development and supporting an average 18-24 month IND timeline.
The heart is a common site for both intended therapeutic action and unintended non-target tissue biodistribution for many biologic therapies. For AAV-based programs, vector design directly influences cardiac tropism. Engineering AAV9 variants to modulate galactose binding, for example, can significantly alter biodistribution between the liver and heart.
Interpreting these effects requires a deep understanding of translational biology. Cross-species differences in glycan avidity can lead to variable vector uptake and subsequent biological effects between preclinical models. A pathology finding in one species may not directly translate to another without this molecular context. Our pathology team specializes in this level of integrated analysis.
Our GxP-compliant evaluation workflow includes:
-
Expert Pathologist Review: All tissues are evaluated by board-certified pathologists with specific expertise in the unique tissue responses elicited by advanced therapies.
-
Advanced Modalities: We utilize a full suite of techniques, including immunohistochemistry (IHC), in situ hybridization (ISH), and digital pathology for quantitative analysis.
-
Integrated Data Correlation: Histology findings are never viewed in isolation. We correlate cellular-level observations with biodistribution, biomarker, and clinical pathology data to build a comprehensive safety profile.
| Capability |
Standard Toxicology Screen |
Franklin Biolabs Biologics-Focused Pathology |
| Pathologist Expertise |
General toxicology focus |
Specialized in gene therapy, cell therapy, & RNA therapeutics |
| Data Integration |
Siloed pathology report |
Correlated with vector biodistribution & molecular data |
| Contextual Analysis |
Standard species background findings |
Deep historical data on vector-specific artifacts & responses |
| Reporting |
Descriptive findings |
Interpretive, IND-focused report with clear risk assessment |
All programs are conducted in our >100,000 sq ft, USDA-registered facility. Through our strategic partnerships, we ensure all studies adhere to the highest ethical standards, including those of AAALAC International. We rigorously apply the 3Rs (Replacement, Reduction, and Refinement) to every program.
*
This rigorous, welfare-focused approach has supported a legacy of excellence, contributing to a 100% IND success rate for programs since 2019. The Franklin Biolabs brand, launched in 2024, is built upon this proven foundation of scientific and ethical execution.
